Eventide Asset Management, LLC Zymeworks Inc. Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $15.4 Million - $43.5 Million	2,561,065 Added 90.85%	5,380,200 $35.2 Million
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $13.8 Million - $26.7 Million	-910,054 Reduced 24.4%	2,819,135 $46.2 Million
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $14.5 Million - $19.7 Million	528,461 Added 16.51%	3,729,189 $108 Million
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $47.8 Million - $68.9 Million	1,802,774 Added 128.96%	3,200,728 $111 Million
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $41.7 Million - $79.4 Million	1,397,954 New	1,397,954 $44.1 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $917M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.